Literature DB >> 14980191

Formoterol vs. albuterol administered via Turbuhaler system in the emergency treatment of acute asthma in children.

L Avila-Castañón1, B Casas-Becerra, B E Del Río-Navarro, Y Velázquez-Armenta, J J L Sienra-Monge.   

Abstract

BACKGROUND: Formoterol is a new beta 2 agonist with a duration of 8-12 hours. Albuterol is a beta 2-agonist with rapid onset of action and a duration of approximately 6 hours.
OBJECTIVE: The aim of the present study was to compare the onset of action between formoterol and albuterol, both administered through a Turbohaler. MATERIAL AND
METHOD: In a double-blind, parallel-group study design 36 patients were randomly allocated to receive either formoterol 12 microg or salbutamol 200 microg. The two drugs were administered through a Turbohaler system. Response (% forced expiratory volume in one second [FEV1]) was evaluated 3, 30 and 60 minutes after drug administration.
RESULTS: The %FEV1 values at 3, 30 and 60 minutes were similar in both groups: 82 15.0 for formoterol and 82 14.4 for albuterol at 60 minutes (p > 0.05).
CONCLUSIONS: Formoterol 12 microg has a similar onset of action and potency to albuterol 200 microg when administered via a Turbuhaler in children with a mild acute asthma crisis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980191     DOI: 10.1016/s0301-0546(04)79218-6

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  2 in total

Review 1.  Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options.

Authors:  Tomasz Grzelewski; Iwona Stelmach
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

2.  Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial.

Authors:  Jenish J Arun; Rakesh Lodha; Sushil K Kabra
Journal:  BMC Pediatr       Date:  2012-03-07       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.